The United States (US) Food and Drug Administration (FDA) has approved brentuximab vedotin (BV) in combination with lenalidomide and a rituximab product (Len + R) for adults with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more systemic therapies, including those with diffuse LBCL (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), who are ineligible for autologous stem cell transplantation (auto-HSCT) or CAR T-cell therapy.¹

Acute promyelocytic leukemia (APL) is a rapidly fatal disease without timely treatment.¹ A recent breakthrough from the University of Hong Kong’s LKS Faculty of Medicine (HKUMed) is changing the global treatment landscape of APL with the development of an oral formulation of arsenic trioxide (oral-ATO).^2-7 Backed by over 20 years of clinical data, oral-ATO has now received orphan drug designation (ODD) from both the United States (US) Food and Drug Administration (FDA) and European Medicines Agency (EMA).^1,8,9 Led by Dr. Singh, Gill Harinder Harry, Clinical Associate Professor at HKUMed, the team is pioneering a new era in APL treatment, bringing this life-saving innovation from Hong Kong to the global stage.^2,7

Myelofibrosis (MF) is a hematologic disorder characterized by splenomegaly, constitutional symptoms, ineffective hematopoiesis, and an increased risk of leukemic transformation.